Boston, Massachusetts, USA

Rhythm Pharmaceuticals

US biotechnology company focused on rare forms of obesity caused by disruption of the MC4R pathway, a brain hunger-and-energy signalling route. Its product IMCIVREE (setmelanotide) is an MC4R agonist. The company states it holds worldwide rights to it, and that it is approved or authorised in the United States, the European Union, Great Britain, Canada and other places for specific rare conditions.

Worldwide rights and approvals

In its 10-Q for the period ended June 30, 2026, Rhythm describes IMCIVREE as an MC4R agonist for which it holds worldwide rights, approved or authorized in the United States, European Union, Great Britain, Canada and other countries and regions.[src]

Acquired hypothalamic obesity label expansion

Rhythm's 10-Q states that IMCIVREE's label expansion to treat patients with acquired hypothalamic obesity was approved by the US FDA on 2026-03-19, and that a similar expansion of its EU marketing authorisation was approved by the European Commission on 2026-04-30.[src]

2025 net product revenue

Rhythm reported total net product revenue of US$194.8 million for 2025 (US$133.6 million US and US$61.2 million international), compared with US$130.1 million in 2024.[src]

Second quarter 2026 net product revenue

Rhythm reported net product revenue of US$71.3 million for the three months ended June 30, 2026, compared with US$48.5 million a year earlier (US$131.4 million for the six months).[src]